Biocon has kicked off FY26 with confidence and is building momentum, setting the tone for a robust year ahead. Powered by strong gains in Biosimilars, steady growth in CRDMO, and a resilient performance in Generics, the quarter reflects more than just numbers, it's a testament to the company's ability to adapt to change and seize … Continue reading Biocon Q1FY26 Earnings is well-positioned for contined momentum and sustained growth
Navigating the Complexities of Peaks and Attributes in Biopharmaceuticals Using Mass Spectrometry-based Multi-Attribute Method (MAM)
Summary: Biosimilars present unique development challenges, but the Mass Spectrometry-based Multi-Attribute Method (MAM) offers a deeper understanding of molecule attributes by analyzing multiple factors in a single workflow. This advanced technique ensures efficient analysis, reduces variability, and maintains the consistent quality and safety of biosimilars. Biological medicines (biopharmaceutical) have transformed the way we treat chronic … Continue reading Navigating the Complexities of Peaks and Attributes in Biopharmaceuticals Using Mass Spectrometry-based Multi-Attribute Method (MAM)
Global Bio India 2024: Biocon Group Playing a Critical Role in Realizing India’s Bioeconomy Potential
Biocon Group participated at the recently concluded Global Bio-India 2024 (GBI 2024), a Government of India initiative under the Department of Biotechnology. The 4th Edition of the GBI 2024, held during September 12-14 in New Delhi witnessed a large representation from key stakeholders in the biotechnology sector, demonstrating India’s biotech potential to the world. In … Continue reading Global Bio India 2024: Biocon Group Playing a Critical Role in Realizing India’s Bioeconomy Potential
Biocon Biologics Reports a Healthy Business Performance in July-September Quarter
The world is just emerging from the economic impact of the COVID-19 pandemic. The people who suffered the economic fallout of the pandemic as their incomes shrunk, urgently need of access to cheaper drugs. This has been the case not only in the emerging markets, but also in the developed countries. Generics and biosimilars which … Continue reading Biocon Biologics Reports a Healthy Business Performance in July-September Quarter
Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
The global economy is in its steepest slowdown since 1970. The IMF has forecast that global economic growth will slow to 3.2% in 2022 and 2.9% in 2023 from 6.1% in 2021. While high inflation continues to make headlines across the globe, spiralling healthcare costs need to be addressed. Biosimilars, which provide affordable access to … Continue reading Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
Biocon's Chairperson Kiran Mazumdar-Shaw in a QnA with FE’s Srinath Srinivasan, talks about the bold moves Biocon Biologics is making since 2021, including the recent acquisition of Viatris’ global biosimilars business, which will provide it a direct entry into the US & Europe with the acquired commercial engine in developed and key emerging markets. This … Continue reading Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
Biocon developing 20 biosimilar products for global markets
India's premier biopharmaceutical company Biocon is working on a pipeline of 20 biosimilar drugs or similar but not identical copy of biologic medicines, to tap the upcoming huge opportunity. Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products. It has biosimilars in oncology like … Continue reading Biocon developing 20 biosimilar products for global markets
A Blog by Biocon 